AXA Gestione
Criteri Gestione verificati 4/4
AXA Il CEO è Thomas Buberl, nominato in Sep2016, e ha un mandato di 9.67 anni. la retribuzione annua totale è € 6.14M, composta da 26.9% di stipendio e 73.1% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.062% delle azioni della società, per un valore di € 50.75M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 6 anni e 5.9 anni.
Informazioni chiave
Thomas Buberl
Amministratore delegato
€6.1m
Compenso totale
| Percentuale dello stipendio del CEO | 26.85% |
| Mandato del CEO | 9.7yrs |
| Proprietà del CEO | 0.06% |
| Durata media del management | 6yrs |
| Durata media del Consiglio di amministrazione | 5.9yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Aggiornamento della narrazione • May 08
CS: Technical And Fee-Based Shift Plus Buybacks Will Support Measured Re-Rating
AXA's fair value estimate edges higher to €46.12 from €46.07 as analysts refine assumptions around revenue growth, profit margins and future P/E, supported by a series of recent price target increases and bullish initiations on the stock. Analyst Commentary Recent Street research around AXA has been active, with several price target revisions and fresh initiations feeding into the updated fair value estimate.Aggiornamento della narrazione • Apr 22
CS: Technical And Fee-Based Earnings Mix Will Support Re-Rating As Discount Persists
Analysts have nudged their average price target for AXA slightly higher to about €46.07. This reflects modest tweaks to assumptions around discount rates, profit margins and future P/E multiples, alongside recent Street research that includes both upward and downward target revisions clustered around the €46 to €50 range.Aggiornamento della narrazione • Apr 07
CS: Technical And Fee-Based Earnings Shift Will Support Re-Rating As Discount Persists
AXA's analyst price targets have edged higher into a €46 to €50.70 range, as analysts point to improved profitability from technical insurance and fee-based earnings, along with what they view as an ongoing discount to European composite peers. Analyst Commentary Recent research points to a cluster of higher price targets for AXA, with analysts largely focused on the mix of technical insurance and fee-based earnings and how that feeds into profitability, earnings stability, and valuation relative to European peers.Aggiornamento della narrazione • Mar 24
CS: Technical And Fee-Based Shift Will Support Re-Rating As Discount Persists
Analysts have nudged AXA's average price target higher to around €48 to €51, citing improved profitability from its focus on technical insurance and fee-based earnings and pointing out that the current valuation still sits at a discount to European composite peers. Analyst Commentary Recent Street research has tilted positive on AXA, with several banks lifting their price targets into a relatively tight band between €46 and about €51.Aggiornamento della narrazione • Mar 10
CS: Technical And Fee-Based Shift Will Support Re-Rating Versus European Composite Peers
Our AXA fair value estimate has been adjusted from €45.27 to €46.05. This reflects higher analyst price targets in the €46 to €50.70 range and their focus on improved profitability, lower earnings volatility and a reduced P/E assumption.Aggiornamento della narrazione • Feb 23
CS: Technical And Fee-Based Shift Will Support Higher Future Earnings Multiple
Analysts have nudged their price target for AXA slightly higher to about €45.27 from roughly €45.11, citing continued focus on technical insurance and fee-based earnings that they say is supporting improved profitability and a higher assumed future P/E multiple. Analyst Commentary Bullish Takeaways Bullish analysts point to the shift towards technical insurance and fee-based earnings as a key support for more stable and higher quality profit streams, which they see as supportive of a stronger P/E multiple over time.Aggiornamento della narrazione • Feb 08
CS: Slightly Lower Discount Rate Will Support Forward Earnings Appeal
The analyst fair value estimate for AXA has been adjusted slightly higher to €45.11 from €45.06, as analysts refine their assumptions around discount rates, revenue growth, profit margins and future P/E multiples. Valuation Changes Fair Value Estimate adjusted slightly higher to €45.11 from €45.06.Aggiornamento della narrazione • Jan 24
CS: Stable Assumptions And Slightly Higher Required Return Will Support Forward Earnings Appeal
Analysts have slightly raised their fair value estimate for AXA to €45.06 from €44.98, citing adjusted assumptions for the discount rate, revenue growth, profit margin and future P/E that together support a marginally higher price target. Valuation Changes Fair value estimate is now set at €45.06, up slightly from €44.98, reflecting a very small adjustment in the model.Aggiornamento della narrazione • Jan 10
CS: Stable Assumptions And Slightly Lower P/E Will Support Forward Earnings Appeal
Analysts have reduced their price target for AXA slightly to about €45, reflecting small adjustments to fair value estimates, discount rate assumptions and future P/E expectations, while keeping revenue growth and profit margin forecasts broadly unchanged. Valuation Changes Fair Value: Adjusted slightly from €45.07 to €44.98, indicating a very small reduction in the estimated fair value per share.Aggiornamento della narrazione • Dec 17
CS: Lower Discount Rate Will Support Stronger Forward Earnings Appeal
Analysts have nudged their price target on AXA slightly higher to approximately €45.07 from about €45.04, citing a marginally lower discount rate and modest improvements in projected profit margins that together support a slightly richer valuation multiple. Valuation Changes Fair Value has risen slightly from approximately €45.04 to about €45.07, reflecting a marginal uplift in the intrinsic valuation estimate.Aggiornamento della narrazione • Dec 03
CS: Modestly Higher Future Multiple Will Support Attractive Upside Potential
Analysts have modestly raised their price target on AXA to €45.04, citing a slightly higher assumed future price to earnings multiple, which more than offsets marginal adjustments to the discount rate and profit margin forecasts. Valuation Changes Fair Value Estimate unchanged at approximately €45.04 per share, indicating no revision to the intrinsic value assessment.Aggiornamento della narrazione • Nov 19
CS: Strong Profit Margins And Stable P/E Will Drive Future Gains
Analysts have slightly raised their price target for AXA, increasing it from €44.96 to €45.04. This change is based on modest adjustments to projected revenue growth, profit margins, and discount rates.Aggiornamento della narrazione • Nov 02
CS: Rising Profit Margins And Multiples Will Drive Global Expansion
Analysts have slightly raised their price target for AXA from €44.58 to €44.96, citing incremental improvements in profit margin and expected future earnings multiples as key factors supporting the revision. Valuation Changes Fair Value has increased slightly from €44.58 to €44.96.Articolo di analisi • Aug 05
These Analysts Think AXA SA's (EPA:CS) Sales Are Under Threat
ENXTPA:CS 1 Year Share Price vs Fair Value Explore AXA's Fair Values from the Community and select yours One thing we...Articolo di analisi • Jul 04
Here's Why AXA (EPA:CS) Has Caught The Eye Of Investors
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...
Nuova narrazione • Nov 07
Calculated Market Expansion And Innovative Products Drive Revenue Growth And Profitability
AXA's disciplined pricing and focus on operational excellence aim to enhance profitability in international markets.Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Utili della società |
|---|---|---|---|
| Dec 31 2025 | €6m | €2m | €7b |
| Sep 30 2025 | n/a | n/a | €7b |
| Jun 30 2025 | n/a | n/a | €7b |
| Mar 31 2025 | n/a | n/a | €7b |
| Dec 31 2024 | €6m | €2m | €7b |
| Sep 30 2024 | n/a | n/a | €7b |
| Jun 30 2024 | n/a | n/a | €7b |
| Mar 31 2024 | n/a | n/a | €7b |
| Dec 31 2023 | €6m | €2m | €7b |
| Sep 30 2023 | n/a | n/a | €6b |
| Jun 30 2023 | n/a | n/a | €5b |
| Mar 31 2023 | n/a | n/a | €5b |
| Dec 31 2022 | €5m | €2m | €5b |
| Sep 30 2022 | n/a | n/a | €6b |
| Jun 30 2022 | n/a | n/a | €7b |
| Mar 31 2022 | n/a | n/a | €7b |
| Dec 31 2021 | €5m | €1m | €7b |
| Sep 30 2021 | n/a | n/a | €6b |
| Jun 30 2021 | n/a | n/a | €6b |
| Mar 31 2021 | n/a | n/a | €4b |
| Dec 31 2020 | €4m | €1m | €3b |
| Jun 30 2020 | n/a | n/a | €3b |
| Mar 31 2020 | n/a | n/a | €3b |
| Dec 31 2019 | €5m | €3m | €4b |
Compensazione vs Mercato: La retribuzione totale di Thomas ($USD 7.14M ) è circa la media per le aziende di dimensioni simili nel mercato French ($USD 5.49M ).
Compensazione vs guadagni: La retribuzione di Thomas è stata coerente con le performance aziendali dell'ultimo anno.
AMMINISTRATORE DELEGATO
Thomas Buberl (52 yo)
9.7yrs
Mandato
€6,144,119
Compensazione
Dr. Thomas Buberl, Ph D., is Independent Director of International Business Machines Corporation from April 28, 2020. Dr. Buberl is CEO & Director of AXA SA from September 01, 2016.Dr. Buberl is CEO & Dir...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| CEO & Director | 9.7yrs | €6.14m | 0.062% € 50.8m | |
| Group General Counsel & Employee Shareholders Representative Director | 9.9yrs | €106.42k | 0.0089% € 7.3m | |
| Group Chief Financial Officer | 4.8yrs | Nessun dato | Nessun dato | |
| Chief Accounting & Reporting Officer | no data | Nessun dato | Nessun dato | |
| Group Chief Technology & AI Officer | 1.3yrs | Nessun dato | Nessun dato | |
| Group Chief Strategy Officer & Head of Investor Relations | 3.7yrs | Nessun dato | Nessun dato | |
| Group Chief Communication | 7.2yrs | Nessun dato | Nessun dato | |
| Deputy General Secretary | 8.5yrs | Nessun dato | Nessun dato | |
| Chief Executive Officer of International Markets | no data | Nessun dato | Nessun dato | |
| Global Head of Finance | 1.3yrs | Nessun dato | Nessun dato | |
| Chief Executive Officer of European Markets & Health | 9.4yrs | Nessun dato | Nessun dato | |
| Chief Transformation Officer for European Markets & Health | 2.8yrs | Nessun dato | Nessun dato |
6.0yrs
Durata media
51.5yo
Età media
Gestione esperta: Il team dirigenziale di CS è esperto e expertise (durata media dell'incarico 6 anni).
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| CEO & Director | 9.7yrs | €6.14m | 0.062% € 50.8m | |
| Group General Counsel & Employee Shareholders Representative Director | 5.9yrs | €106.42k | 0.0089% € 7.3m | |
| Honorary Chairman | 16.1yrs | Nessun dato | Nessun dato | |
| Independent Director | 10.1yrs | €172.04k | 0.00035% € 288.5k | |
| Director | 4.1yrs | €171.05k | 0.024% € 19.5m | |
| Independent Director | 5.1yrs | €233.81k | 0.00037% € 305.0k | |
| Independent Director | 5.1yrs | €173.92k | 0.00024% € 197.9k | |
| Independent Chairman of the Board | 5.9yrs | Nessun dato | 0.00021% € 173.1k | |
| Employees Representative Director | 7.9yrs | €106.42k | 0.000020% € 16.5k | |
| Employees Representative Director | 7.9yrs | €140.17k | 0.00014% € 115.4k | |
| Independent Director | 1.3yrs | €184.14k | Nessun dato | |
| Independent Director | 5.9yrs | €140.17k | 0.00019% € 156.6k |
5.9yrs
Durata media
60.5yo
Età media
Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di CS sono considerati esperti (durata media dell'incarico 5.9 anni).
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/05/21 23:08 |
| Prezzo dell'azione a fine giornata | 2026/05/21 00:00 |
| Utili | 2025/12/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
AXA SA è coperta da 35 analisti. 12 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Markus Mayer | Baader Helvea Equity Research |
| null null | Banco de Sabadell. S.A. |
| Valvanera Gómez Pastor | Banco Santander |